
CureVac N.V. CVAC
Quartalsbericht 2022-Q2
hinzugefügt 18.08.2022
CureVac N.V. Langfristige Verbindlichkeiten 2011-2026 | CVAC
Langfristige Verbindlichkeiten Jährlich CureVac N.V.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 112 M | 552 M | 145 M | 65.4 M | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 552 M | 65.4 M | 219 M |
Langfristige Verbindlichkeiten Vierteljährlich CureVac N.V.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 107 M | 114 M | 112 M | 154 M | - | - | 552 M | - | - | - | 145 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 552 M | 107 M | 197 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
263 M | $ 18.46 | -0.22 % | $ 2.72 B | ||
|
Amgen
AMGN
|
37.2 B | $ 344.63 | 0.8 % | $ 185 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
686 M | $ 70.06 | 1.05 % | $ 9.37 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Biogen
BIIB
|
9.03 B | $ 179.46 | -0.24 % | $ 26.1 B | ||
|
Aytu BioScience
AYTU
|
42.1 M | $ 2.7 | 3.85 % | $ 17 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
158 M | $ 2.6 | -5.45 % | $ 146 M | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.14 | -0.95 % | $ 7.55 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 4.32 | 7.67 % | $ 9.4 B | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Aptose Biosciences
APTO
|
10.2 M | - | -45.71 % | $ 1.2 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Compugen Ltd.
CGEN
|
39.9 M | $ 1.83 | -0.3 % | $ 164 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
168 M | $ 1.41 | - | $ 264 M | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Celldex Therapeutics
CLDX
|
17.3 M | $ 24.98 | 1.54 % | $ 1.61 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
101 M | $ 226.97 | 0.38 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | ||
|
Cellectis S.A.
CLLS
|
109 M | $ 3.86 | 1.72 % | $ 116 M | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
BioNTech SE
BNTX
|
341 M | $ 109.35 | -3.87 % | $ 27.2 B | ||
|
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.38 | 0.73 % | $ 352 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
2.29 M | $ 42.1 | 5.59 % | $ 4.35 B | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
648 K | $ 24.77 | 1.93 % | $ 2.93 B | ||
|
Cardiff Oncology
CRDF
|
451 K | $ 1.7 | -3.14 % | $ 81 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M | ||
|
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | ||
|
Amneal Pharmaceuticals
AMRX
|
2.42 B | $ 13.96 | 2.01 % | $ 4.31 B | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
44.7 M | $ 6.58 | - | $ 1.36 B |